Milwaukee

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Asthma2 trials
• HIV2 trials
• Multiple myeloma2 trials
• Head and neck cancer1 trial
• Lung cancer1 trial
• Ovarian cancer1 trial

Phase

• Phase 35 trials
• Phase 12 trials
• Phase 22 trials

Status

• Active, not recruiting7 trials
• Completed1 trial
• Withdrawn1 trial

Lead sponsor

• GlaxoSmithKline5 trials
• Tesaro, Inc.2 trials
• ViiV Healthcare2 trials

Running trials

• Active, not recruiting

  A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

  NCT06694805· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

  NCT06062420· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

  NCT05996471· Phase 2· ViiV Healthcare· Source

• Active, not recruiting

  A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

  NCT05757102· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT04162210· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

  NCT02655016· Phase 3· Tesaro, Inc.· Source

• Active, not recruiting

  Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

  NCT02715284· Phase 1· Tesaro, Inc.· Source

Closed trials

• Withdrawn

  A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function

  NCT04398680· Phase 1· GlaxoSmithKline· Source

• Completed

  A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718103· Phase 3· GlaxoSmithKline· Source